Literature DB >> 29499417

Biochemical transformation of calciprotein particles in uraemia.

Edward R Smith1, Tim D Hewitson2, Eric Hanssen3, Stephen G Holt2.   

Abstract

Calciprotein particles (CPP) have emerged as nanoscale mediators of phosphate-induced toxicity in Chronic Kidney Disease (CKD). Uraemia favors ripening of the particle mineral content from the amorphous (CPP-I) to the crystalline state (CPP-II) but the pathophysiological significance of this transformation is uncertain. Clinical studies suggest an association between CPP ripening and inflammation, vascular dysfunction and mortality. Although ripening has been modelled in vitro, it is unknown whether particles synthesised in serum resemble their in vivo counterparts. Here we show that in vitro formation and ripening of CPP in uraemic serum is characterised by extensive physiochemical rearrangements involving the accretion of mineral, loss of surface charge and transformation of the mineral phase from a spherical arrangement of diffuse domains of amorphous calcium phosphate to densely-packed lamellar aggregates of crystalline hydroxyapatite. These physiochemical changes were paralleled by enrichment with small soluble apolipoproteins, complement factors and the binding of fatty acids. In comparison, endogenous CPP represent a highly heterogeneous mixture of particles with characteristics mostly intermediate to synthetic CPP-I and CPP-II, but are also uniquely enriched for carbonate-substituted apatite, DNA fragments, small RNA and microbe-derived components. Pathway analysis of protein enrichment predicted the activation of cell death and pro-inflammatory processes by endogenous CPP and synthetic CPP-II alike. This comprehensive characterisation validates the use of CPP-II generated in uraemic serum as in vitro equivalents of their endogenous counterparts and provides insight into the nature and pathological significance of CPP in CKD, which may act as vehicles for various bioactive ligands.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calciprotein particles; Chronic kidney disease; Fetuin-A; Mineral; Proteomics; Ultrastructure

Mesh:

Substances:

Year:  2018        PMID: 29499417     DOI: 10.1016/j.bone.2018.02.023

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  22 in total

1.  Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study.

Authors:  Joshua D Bundy; Xuan Cai; Julia J Scialla; Mirela A Dobre; Jing Chen; Chi-Yuan Hsu; Mary B Leonard; Alan S Go; Panduranga S Rao; James P Lash; Raymond R Townsend; Harold I Feldman; Ian H de Boer; Geoffrey A Block; Myles Wolf; Edward R Smith; Andreas Pasch; Tamara Isakova
Journal:  Am J Kidney Dis       Date:  2019-03-29       Impact factor: 8.860

2.  Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial.

Authors:  Edward R Smith; Fei Fei M Pan; Tim D Hewitson; Nigel D Toussaint; Stephen G Holt
Journal:  Kidney Int Rep       Date:  2020-06-29

3.  Serum Calcification Propensity and Clinical Events in CKD.

Authors:  Joshua D Bundy; Xuan Cai; Rupal C Mehta; Julia J Scialla; Ian H de Boer; Chi-Yuan Hsu; Alan S Go; Mirela A Dobre; Jing Chen; Panduranga S Rao; Mary B Leonard; James P Lash; Geoffrey A Block; Raymond R Townsend; Harold I Feldman; Edward R Smith; Andreas Pasch; Tamara Isakova
Journal:  Clin J Am Soc Nephrol       Date:  2019-10-28       Impact factor: 8.237

4.  Live Imaging of Calciprotein Particle Clearance and Receptor Mediated Uptake: Role of Calciprotein Monomers.

Authors:  Sina Koeppert; Ahmed Ghallab; Sarah Peglow; Camilla Franziska Winkler; Steffen Graeber; Andrea Büscher; Jan Georg Hengstler; Willi Jahnen-Dechent
Journal:  Front Cell Dev Biol       Date:  2021-04-29

5.  Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function.

Authors:  Mark K Tiong; Michael M X Cai; Nigel D Toussaint; Sven-Jean Tan; Andreas Pasch; Edward R Smith
Journal:  Sci Rep       Date:  2022-05-05       Impact factor: 4.996

Review 6.  Therapeutic Interference With Vascular Calcification-Lessons From Klotho-Hypomorphic Mice and Beyond.

Authors:  Florian Lang; Christina Leibrock; Lisann Pelzl; Meinrad Gawaz; Burkert Pieske; Ioana Alesutan; Jakob Voelkl
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-04       Impact factor: 5.555

7.  Cellular Clearance and Biological Activity of Calciprotein Particles Depend on Their Maturation State and Crystallinity.

Authors:  Sina Köppert; Andrea Büscher; Anne Babler; Ahmed Ghallab; Eva M Buhl; Eicke Latz; Jan G Hengstler; Edward R Smith; Willi Jahnen-Dechent
Journal:  Front Immunol       Date:  2018-09-04       Impact factor: 7.561

8.  Phosphate binding by sucroferric oxyhydroxide ameliorates renal injury in the remnant kidney model.

Authors:  Yoshikazu Nemoto; Takanori Kumagai; Kenichi Ishizawa; Yutaka Miura; Takeshi Shiraishi; Chikayuki Morimoto; Kazuhiro Sakai; Hiroki Omizo; Osamu Yamazaki; Yoshifuru Tamura; Yoshihide Fujigaki; Hiroshi Kawachi; Makoto Kuro-O; Shunya Uchida; Shigeru Shibata
Journal:  Sci Rep       Date:  2019-02-11       Impact factor: 4.379

9.  Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease.

Authors:  Mark K Tiong; Edward R Smith; Nigel D Toussaint; Hasan F Al-Khayyat; Stephen G Holt
Journal:  JBMR Plus       Date:  2021-05-05

10.  Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.

Authors:  Irene Ruderman; Edward R Smith; Nigel D Toussaint; Tim D Hewitson; Stephen G Holt
Journal:  BMC Nephrol       Date:  2018-05-15       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.